ATRA — Atara Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $46.62m
- $45.38m
- $128.94m
- 28
- 51
- 80
- 53
Annual income statement for Atara Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 20.3 | 63.6 | 8.57 | 129 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | -0.313 | 108 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 309 | 361 | 344 | 285 | 212 |
| Operating Profit | -309 | -340 | -281 | -276 | -83.4 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -307 | -340 | -228 | -276 | -85.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -307 | -340 | -228 | -276 | -85.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -307 | -340 | -228 | -276 | -85.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -307 | -340 | -228 | -276 | -85.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -104 | -90.8 | -63 | -64.1 | -11 |